1. HBW Insight
  2. >>Geography
  3. >>North America
  4. >>United States

FDA-Proposed Talc Testing Methods Likely Would Find Particles Of Concern; Then What?

 
• By Ryan Nelson

The FDA is focused on driving adoption of more sensitive, standardized testing methods for assessing cosmetic talc purity, which it believes would yield more consistent results across labs. This would help to inform research into the health implications of trace levels of asbestos and other elongate mineral particles in talc; in the interim it could to be damaging to companies that supply or use that talc.

Asbestos

Asbestos’ reputation precedes it, but the health implications of exposure to miniscule amounts of the substance and other elongate mineral particles (EMPs) in cosmetic talc are not well understood.

The US Food and Drug Administration and partners in the Interagency Working Group on Asbestos in Consumer Products (IWGACP) believe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 
• By Eileen Francis

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 
• By Derrick Gingery

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 
• By Malcolm Spicer

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.